{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:16:33Z","timestamp":1788592593392,"version":"build-2803163510"},"reference-count":54,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S1092852920001893_sec1\"><jats:title>Background<\/jats:title><jats:p>Minimal long-term benefit: Risk data are available regarding antipsychotic treatments for schizophrenia in pediatric populations. This study evaluated the long-term safety, tolerability, and effectiveness of lurasidone in adolescents with schizophrenia.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852920001893_sec2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>Patients aged from 13 to 17 who completed 6\u00a0weeks of double-blind (DB), placebo-controlled treatment with lurasidone were enrolled in a 2-year, open-label (OL), flexible dose (20-80\u00a0mg\/day) lurasidone treatment study. Safety was assessed via spontaneous reporting, rating scales, body weight measurement, metabolic, and prolactin testing. Effectiveness measures included the Positive and Negative Syndrome Scale (PANSS) total score.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852920001893_sec3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>About 271 patients completed 6\u00a0weeks of DB treatment and entered the 2-year OL extension study. Altogether, 42.4% discontinued prematurely, 10.7% due to adverse events. During OL treatment, the most common adverse events were headache (24.0%); anxiety (12.9%), schizophrenia, and nausea (12.5%); sedation\/somnolence (12.2%); and nasopharyngitis (8.9%). Minimal changes were observed on metabolic parameters and prolactin. Mean change from DB baseline in weight at week 52 and week 104 was +3.3\u00a0kg and\u00a0+\u00a04.9\u00a0kg, respectively, compared to an expected weight gain of +3.4\u00a0kg and\u00a0+\u00a05.7\u00a0kg, respectively, based on the sex- and age-matched US Center for Disease Control normative data. Continued improvement was observed in PANSS total score, with mean change from OL baseline of \u221215.6 at week 52 and \u221218.4 at week 104.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852920001893_sec4\" sec-type=\"conclusions\"><jats:title>Conclusion<\/jats:title><jats:p>In adolescents with schizophrenia, long-term lurasidone treatment was associated with minimal effects on body weight, lipids, glycemic indices, and prolactin. Continued improvement in symptoms of schizophrenia was observed over 2\u00a0years of lurasidone treatment.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852920001893","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T04:42:46Z","timestamp":1603168966000},"page":"118-128","source":"Crossref","is-referenced-by-count":21,"title":["Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study"],"prefix":"10.1017","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Findling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Pikalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"S1092852920001893_r3","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbw011"},{"key":"S1092852920001893_r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.01.009"},{"key":"S1092852920001893_r10","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e32835dcc2a"},{"key":"S1092852920001893_r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.07.007"},{"key":"S1092852920001893_r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.2923"},{"key":"S1092852920001893_r37","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"S1092852920001893_r34","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0189"},{"key":"S1092852920001893_r30","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115620460"},{"key":"S1092852920001893_r53","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2012.0068"},{"key":"S1092852920001893_r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.03.013"},{"key":"S1092852920001893_r13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"S1092852920001893_r41","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"S1092852920001893_r1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.162.1.80"},{"key":"S1092852920001893_r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.02.008"},{"key":"S1092852920001893_r29","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-012-2838-2"},{"key":"S1092852920001893_r44","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000198590.38325.81"},{"key":"S1092852920001893_r35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1987.tb10566.x"},{"key":"S1092852920001893_r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2006.09.008"},{"key":"S1092852920001893_r42","volume-title":"ECDEU Assessment Manual for Psychopharmacology Revised","author":"Guy","year":"1976"},{"key":"S1092852920001893_r51","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070984"},{"key":"S1092852920001893_r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2017.10.006"},{"key":"S1092852920001893_r22","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.167346"},{"key":"S1092852920001893_r24","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10060907"},{"key":"S1092852920001893_r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.09.011"},{"key":"S1092852920001893_r33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300027"},{"key":"S1092852920001893_r5","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.101543"},{"key":"S1092852920001893_r43","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790100074010"},{"key":"S1092852920001893_r17","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0141"},{"key":"S1092852920001893_r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2015.06.015"},{"key":"S1092852920001893_r19","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20765"},{"key":"S1092852920001893_r11","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12412"},{"key":"S1092852920001893_r50","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070985"},{"key":"S1092852920001893_r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2017.06.013"},{"key":"S1092852920001893_r8","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e32833b027e"},{"key":"S1092852920001893_r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2013.01.020"},{"key":"S1092852920001893_r12","first-page":"26","article-title":"Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents","volume":"69","author":"Correll","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"S1092852920001893_r31","doi-asserted-by":"publisher","DOI":"10.1192\/pb.bp.114.048793"},{"key":"S1092852920001893_r36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"S1092852920001893_r2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291707009944"},{"key":"S1092852920001893_r47","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.6.1171"},{"key":"S1092852920001893_r54","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0010"},{"key":"S1092852920001893_r49","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.3.441"},{"key":"S1092852920001893_r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2018.03.008"},{"key":"S1092852920001893_r32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93362"},{"key":"S1092852920001893_r40","doi-asserted-by":"publisher","DOI":"10.1093\/arclin\/acp010"},{"key":"S1092852920001893_r4","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291711002960"},{"key":"S1092852920001893_r7","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e31807083fd"},{"key":"S1092852920001893_r23","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04905"},{"key":"S1092852920001893_r38","first-page":"1172","article-title":"How to examine patients using the abnormal involuntary movement scale","volume":"39","author":"Munetz","year":"1988","journal-title":"Hosp Community Psychiatry"},{"key":"S1092852920001893_r25","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32835281ef"},{"key":"S1092852920001893_r48","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.1.45"},{"key":"S1092852920001893_r39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"S1092852920001893_r45","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"S1092852920001893_r20","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2014.0130"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852920001893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T09:20:18Z","timestamp":1644830418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852920001893\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1092852920001893"],"URL":"https:\/\/doi.org\/10.1017\/s1092852920001893","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]}}}